The Phase IIa CLEAR MIND trial will evaluate Lomecel-B’s safety in mild Alzheimer’s Disease (AD) patients. Credit: Gerd Altmann from Pixabay.

Longeveron has concluded subject enrolment in the Phase IIa CLEAR MIND trial of its lead investigational therapeutic candidate, Lomecel-B, for the treatment of Alzheimer’s Disease (AD).

The parallel design, four-arm, randomised clinical trial will assess the safety of single and multiple infusions of two different Lomecel-B dose levels compared to a placebo in mild AD patients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It will be conducted in 48 participants.

The study’s primary endpoint is to assess the safety of Lomecel-B by measuring the occurrence of serious adverse events (SAEs) in the initial 30 days after giving the investigational therapeutic candidate.

Brain volumetry by magnetic resonance imaging (MRI), measures of cognitive function, and biomarkers relevant to inflammation and endothelial/vascular systems are some of the secondary and exploratory endpoints of the study.

The company stated that the Phase IIa CLEAR MIND trial follows the previously announced positive results of the Phase Ib clinical trial of Lomecel-B for AD.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The findings demonstrated that the therapeutic candidate met the trial’s primary endpoint of safety.

Longeveron interim CEO and chief medical officer Chris Min said: “We are pleased to have completed enrolment in our Phase IIa study of Lomecel-BTM for Alzheimer’s Disease.

“We look forward to building on our Phase Ib study, which met its primary endpoint of safety and was published in a leading journal, Alzheimer’s and Dementia, the Journal of the Alzheimer’s Association, this year.

“We are excited to advance our programme designed to assess the therapeutic potential of Lomecel-BTM in patients with AD.”

Lomecel-B is currently being assessed in several clinical trials for the treatment of ageing-related chronic diseases, as well as other life-threatening conditions under the Investigational New Drug (IND) applications, which are approved by the US Food and Drug Administration (FDA).